Tari Ao Whānui

I te 21 o Paenga-whāwhā, 2026, i panuitia e te Center for Drug Assessment (CDE) o te National Medical Products Administration kua tohua te HS-20093 mō te werohanga (risvutatug rezetecan) hei kaitono Breakthrough Therapy mō te maimoatanga o ngā tūroro e pangia ana e te mate pukupuku prostate ātete-whakakorenga matatau...Pānuihia atu»

Nō nā tata nei, i kī te Center for Drug Assessment (CDE) o te National Medical Products Administration (NMPA) o Haina kua whakaaetia te Encorafenib mō te arotake matua. Ka whakamahia ngātahitia me te cetuximab me te tikanga rongoā FOLFOX hei maimoatanga tuatahi mō...Pānuihia atu»

Ina puta ngā kupu "matepukupuku repeure" i runga i tētahi pūrongo tātaritanga—ina koa ka haere tahi me te "25 metastases ate"—he tini ngā whānau kua taka ki te pouri. Ko tēnei mate, e mōhiotia ana ko te "kingi o ngā matepukupuku," i mua i kitea he maha ngā metastases, he maha ngā wā...Pānuihia atu»

Nō nā tata nei, i panuitia e Bayer kua whakaaetia e te Whakahaere Hua Hauora ā-Motu o Haina (NMPA) te rongoā hou e arohia ana, ko te sevabertinib, hei rongoā mō ngā tūroro pakeke e pangia ana e te mate pukupuku pūkahukahu kore-pūtau iti (NSCLC) kāore e taea te tango, e horapa ana rānei, ā, kei a rātou te HER2 (ERBB2) e whakahohe ana i ngā whakarerekētanga...Pānuihia atu»

E ngā Tūroro o te Ao, Ina kei te whawhai koe, kei te rapu rānei i ngā huarahi maimoatanga ngāwari ake, whai hua ake, ka hiahia mātou ki te whakaatu atu ki a koe tētahi hangarau mate pukupuku hou — te Whakaora Wehewehenga Tissue Ultrasound. Kua angitu te whakatinanatanga o tēnei maimoatanga matatau...Pānuihia atu»

Ina taupokina te ora e te mate pukupuku, he pānga nui tō ia whiringa maimoatanga ki te kounga me te mana o taua ora. Mō ngā tūroro kua pakeke haere, he ngoikore te mahi a te manawa, kāore e taea te aro ki te pokanga, ki te rongoā whakamoe rānei, e rapu ana rānei i tētahi huarahi ngāwari hei whawhai i te pukupuku, ko te ...Pānuihia atu»

I te 31 o Poutū-te-rangi, 2026, i tukuna mai e te Pokapū Arotake Rongoā o te Whakahaere Hua Hauora ā-Motu o Haina he pūrongo whakahihiri: kua whakaurua mana a GFH375, i whakawhanakehia e GenFleet Therapeutics, hei "Whakaora Pakari" mō te maimoatanga o ngā tūroro e pangia ana e te mate pukupuku repeure metastatic...Pānuihia atu»

Mō te tini o ngā tūroro mate pukupuku kaumātua me ō rātou whānau, he maha ngā wā ka puta mai te mate ngakaukore i te wā e kitea ai he mate pukupuku. Ina koa ka tūtaki ki te "kingi o ngā mate pukupuku" - te mate pukupuku repeure - ko te mamae nui me te kore e taea te kai he maha ngā wā ka tangohia te mana o ngā tūroro, ka waiho ō rātou whanaunga ki roto i te pouri nui. Ki...Pānuihia atu»

I te 24 o Poutū-te-rangi, 2024, i panuitia e te Pokapū Arotake Rongoā o te Whakahaere Hua Hauora ā-Motu o Haina e whakaarohia ana kia tohua te rongoā auaha a Teclistamab hei rongoā hou mō te maimoatanga monotherapy o ngā tūroro pakeke e hoki whakamuri ana, e uaua ana rānei ki te rongoā...Pānuihia atu»

Nō nā tata nei, i whakaaetia e te National Medical Products Administration (NMPA) tētahi tohu hou mō te antibody-drug conjugate (ADC) Disitamab vedotin hei rongoā mō ngā tūroro mate pukupuku ū pakeke me te HER2-low expression kāore e taea te tango, te metastatic rānei (IHC 1+, IHC 2+/ISH- rānei) me ngā metastases ate, e...Pānuihia atu»

I te 10 o Poutū-te-rangi, 2026, i whakawhiwhia te B7-H3-targeting antibody-drug conjugate (ADC) YL201 auaha mō te werohanga, i whakawhanakehia e MediLink Therapeutics, ki te Breakthrough Therapy Designation e te Center for Drug Evaluation of China's National Medical Products Administration. Ko te tohu kua tohua...Pānuihia atu»

Nō nā tata nei, i whakaaetia mana e te Pokapū Arotake Rongoā (CDE) o te Whakahaere Hua Hauora ā-Motu o Haina te werohanga KSD-101, i whakawhanakehia e Kousai, kia uru ki ngā whakamātautau haumanu. Ehara i te mea koinei anake te kano kano pūtau dendritic tuatahi (kano kano DC) i Haina kua whiwhi i te taupānga FDA IND...Pānuihia atu»